Status:
COMPLETED
Improving Glycemic Control in DM2 Patients in the Ambulatory Setting
Lead Sponsor:
University of Maryland, Baltimore
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
21+ years
Phase:
NA
Brief Summary
More than 10.5% of the US population has diabetes mellitus. The objective of this pilot study is to evaluate whether smart insulin pens combined with CGM devices can improve glucose control in patient...
Detailed Description
Diabetes is affecting millions of Americans. High glucose levels lead to complications such as heart attacks, stroke or blindness. Patients with diabetes need to exercise at least 150 min/week, a goal...
Eligibility Criteria
Inclusion
- Insulin-treated patients with DM2 (treated with basal-bolus insulin regimens (MDI), ± non-insulin medications) and Uncontrolled glycemic control
Exclusion
- History of type 1 DM (DM1)
- Pregnant Patients
- Extensive skin changes/disease or allergies that preclude wearing the CGM sensor
- Subjects who have end-stage renal disease requiring dialysis
- Significant psychiatric illness or any other condition rendering the subject incapable of understanding the objectives and potential consequences of the study
Key Trial Info
Start Date :
August 16 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 9 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04800471
Start Date
August 16 2021
End Date
July 9 2024
Last Update
July 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Baltimore VA Medical Center
Baltimore, Maryland, United States, 21201